Abbott Laboratories

What they make

1 input Abbott Laboratories supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

2 facilities

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

• Did you know2023

  Abbott is publicly known for infant formula (Similac) after the 2022 shortage, but the same company is the world's largest maker of continuous glucose monitors (CGM) — the FreeStyle Libre, worn as a quarter-sized sensor patch on the arm by 5+ million people with diabetes to track blood sugar continuously without fingersticks. FreeStyle Libre is a Class II medical device manufactured in Donegal, Ireland; Similac infant formula is a food product manufactured in Sturgis, Michigan and Columbus, Ohio. These products share only the Abbott corporate umbrella: one is a precision biosensor for chronic disease management, the other is the substitute for human breast milk for infants. Abbott's 2022 Sturgis plant closure (due to Cronobacter bacterial contamination, not related to any medical device issue) simultaneously: triggered a national infant formula emergency (FDA authorized imports from Europe for the first time), affected zero medical device supply, and illustrated how a corporate conglomerate structure can create unexpected supply chain dependencies — the infant formula brand crisis prompted congressional scrutiny of Abbott that temporarily distracted from FreeStyle Libre regulatory submissions.

  Abbott Laboratories ↗

• Chokepoint2014

  Abbott obtained FDA GRAS status in 2014 for 2'-Fucosyllactose (2'-FL), becoming the first company to add a human breast milk sugar to commercial US infant formula. The 2'-FL fermentation process uses engineered E. coli strains and requires biosafety-level-1 fermentation facilities. This creates a regulatory and IP barrier limiting competitive response timelines to 3-5 years. BASF later paid $960M to acquire Glycom (2020) specifically to gain HMO fermentation capability.

  U.S. Food and Drug Administration ↗

• Origin2023

  Abbott Laboratories was founded in 1888 in Chicago by Dr. Wallace Calvin Abbott, a physician who was frustrated by the unreliable dosage of commercially available medicines — tablets and granules varied wildly in their active ingredient content. Abbott developed measured dosimetric granules with precise drug quantities and sold them directly to physicians. This standardization of pharmaceutical dosing is the conceptual origin of modern drug manufacturing quality control. Abbott grew through the 20th century by following a consistent thread: precision in pharmaceutical and nutritional formulation. In 2013, Abbott spun off its pharmaceutical research division as AbbVie (which retained Humira, the world's best-selling drug). Abbott retained medical devices, diagnostics, and nutrition. In 2017, Abbott acquired St. Jude Medical for $25 billion — making them a major cardiac device company. The company founded to standardize aspirin dosages in 1888 is now the company managing continuous glucose sensing in real-time for 5 million diabetes patients and implanting pacemakers in cardiac patients.

  Abbott Laboratories ↗

• Incident2022

  Abbott's Sturgis, Michigan plant — the largest US infant formula facility — was shut down on February 17, 2022 after Cronobacter sakazakii contamination sickened four infants and killed two; national out-of-stock rates surged from 18% (January) to 70% by May 21; President Biden invoked the Defense Production Act and launched 'Operation Fly Formula' (emergency military airlift of imported formula) — the most severe infant food shortage in US history

  PubMed Central / NIH ↗